生物标志物与疗效：我们快达成目标了吗？ - Suppr | 超能文献

Biomarkers and efficacy: are we nearly there yet?

作者信息

Russo A, Rizzo S

机构信息

Section of Medical Oncology, Department of Surgical and Oncological Sciences; Università di Palermo, Palermo, Italy.

Section of Medical Oncology, Department of Surgical and Oncological Sciences; Università di Palermo, Palermo, Italy.

出版信息

Ann Oncol. 2011 Jul;22(7):1469-1470. doi: 10.1093/annonc/mdr258. Epub 2011 May 5.

DOI:10.1093/annonc/mdr258

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Biomarkers and efficacy: are we nearly there yet?生物标志物与疗效：我们快达成目标了吗？

Ann Oncol. 2011 Jul;22(7):1469-1470. doi: 10.1093/annonc/mdr258. Epub 2011 May 5.

2

Managing advanced colorectal cancer: have we reached the PEAK with current therapies?晚期结直肠癌的治疗：我们当前的治疗方法是否已达到顶峰？

J Clin Oncol. 2014 Jul 20;32(21):2200-2. doi: 10.1200/JCO.2014.55.6316. Epub 2014 Jun 16.

3

Treatment of metastatic colon cancer: "the times they are A-changing".转移性结肠癌的治疗：“时代正在改变” 。（注：原句中“A-changing”表述有误，正确的是“a-changing”，这里按正确内容翻译）

J Clin Oncol. 2013 Jun 1;31(16):1913-6. doi: 10.1200/JCO.2013.49.4500. Epub 2013 Apr 29.

4

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.根据生物标志物状态评估西妥昔单抗联合 FOLFOX-4 一线治疗转移性结直肠癌的疗效：OPUS 研究。

Ann Oncol. 2011 Jul;22(7):1535-1546. doi: 10.1093/annonc/mdq632. Epub 2011 Jan 12.

5

Food and Drug Administration approval of cetuximab and a new KRAS genetic test for metastatic colorectal cancer: major advance but just the tip of the biomarker iceberg.

Am J Ther. 2012 Nov;19(6):395-6. doi: 10.1097/MJT.0b013e31826a94d8.

6

FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.根据肿瘤RAS和BRAF突变状态，FOLFOX4联合西妥昔单抗用于先前未治疗的转移性结直肠癌患者：CECOG/CORE 1.2.002研究的更新分析

Clin Colorectal Cancer. 2015 Jun;14(2):91-8. doi: 10.1016/j.clcc.2014.12.003. Epub 2014 Dec 24.

7

When inoperable becomes operable?何时不可手术变为可手术？

J Clin Oncol. 2013 Dec 10;31(35):4474. doi: 10.1200/JCO.2013.51.8837. Epub 2013 Oct 28.

8

Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy.miR-31-3p 的表达与抗 EGFR 治疗的 KRAS 野生型转移性结直肠癌患者的无进展生存期相关。

Clin Cancer Res. 2014 Jun 15;20(12):3338-47. doi: 10.1158/1078-0432.CCR-13-2750. Epub 2014 Apr 25.

9

Complicated puzzle in cetuximab-based chemotherapy: skin toxicity and resection rate in patients with initially unresectable colorectal liver metastases.基于西妥昔单抗的化疗中的复杂难题：初始不可切除的结直肠癌肝转移患者的皮肤毒性和切除率

J Clin Oncol. 2013 Dec 10;31(35):4473. doi: 10.1200/JCO.2013.50.8713. Epub 2013 Oct 28.

10

Can K-ras gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic review.K-ras 基因突变能否作为接受化疗的结直肠癌患者的预后生物标志物？一项荟萃分析和系统评价。

PLoS One. 2013 Oct 21;8(10):e77901. doi: 10.1371/journal.pone.0077901. eCollection 2013.

引用本文的文献

1

Mass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies.基于质谱的血清和血浆肽组分析用于预测实体恶性肿瘤患者的治疗结果

Oncologist. 2014 Oct;19(10):1028-39. doi: 10.1634/theoncologist.2014-0101. Epub 2014 Sep 3.